Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

By S. Malozowski, J. Sahlroot. New England Journal of Medicine, 2007

929 citations recorded by the source corpus.

Subfields: Genetics, Physiology, Surgery

View Paper: https://www.semanticscholar.org/paper/2055482f6102c733cf8ce6dbd87f0a353b44b6a1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Physiology

In Surgery

Citations in the corpus

Inflammasomes in health and disease (2012, background): “, and more importantly from human clinical trials of IL-1 receptor antagonist (IL-1RA) to treat T2DM that demonstrated improved glycaemic control and β-cell functio”
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). (2011, background): “This latter secondary hypothesis reflects IL-1β's implication in autoinflammatory processes related to pancreatic dysfunction, insulin resistance, and diabetogenesis.(34,64) Finally, in exploratory prespecified analyses, CANTOS will also address the impact of IL-1β inhibition with canakinumab on the”
IL‐1, IL‐18, and IL‐33 families of cytokines (2008, methodology): “A double-blind clinical trial was carried out in patients with type 2 diabetes by administering anakinra once daily for 13 weeks (54).”
Mechanisms and functions of inflammasomes. (2014, background): “Anti-IL-1 therapies have proven successful in several of the aforementioned ailments, including type 2 diabetes and juvenile rheumatoid arthritis (Dinarello et al., 2012; Larsen et al., 2007).”
Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome (2012, background): “TXNIP and IL-1b signaling has a role in b cell death in type 1 and type 2 diabetes, raising the possibility that TXNIP-mediated IL-1b induction plays a role in ER stress mediated cell death (Dinarello et al., 2010; Larsen et al., 2007).”
Activation of the Nlrp3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes (2010, background): “, and results of a clinical trial of IL-1 blockade in type 2 diabetes have been very encouragin”
Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention (2014, background): “Salicylates and interleukin-1 antagonists are the representative drugs with immunomodulatory effects in the treatment of T2DM patients, which can lower blood glucose levels and reduce severity and prevalence of the associated complications [152, 153].”
The NALP3/NLRP3 Inflammasome Instigates Obesity-Induced Autoinflammation and Insulin Resistance (2011, methodology): “Consistent with these data, randomized clinical trials have shown that blockade of IL-1β signaling by anakinra, a recombinant human IL-1 receptor antagonist, leads to a sustained reduction in systemic inflammation and improvement of type 2 diabete”
Inflammatory responses and inflammation-associated diseases in organs (2015, background): “Elevated circulating levels of acute-phase proteins, including CRP, fibrinogen, serum amyloid A, plasminogen activator inhibitor, and haptoglobin, along with sialic acid, cytokines, and chemokines, have been observed in patients with T2D.”
Impact of the gut microbiota on inflammation, obesity, and metabolic disease (2016, background): “The production of cytokines such as tumor necrosis factor α (TNF-α) or interleukin (IL)-1β in visceral adipose tissues in rodents and humans affects insulin sensitivity by altering the expression of genes encoding IRS-1, the glucose transporter GLUT4, and PPAR-α [29, 30].”
Caspase functions in cell death and disease. (2013, methodology): “Excessive caspase-1 activity has thus been implicated in T2D etiology.”
Sterile inflammation: sensing and reacting to damage (2010, background): “A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabete”